©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Negative Feedback Regulation and Desensitization of Insulin- and Epidermal Growth Factor-stimulated p21 Activation (*)

(Received for publication, July 10, 1995; and in revised form, August 31, 1995)

W. John Langlois Toshiyasu Sasaoka (1) Alan R. Saltiel (2) Jerrold M. Olefsky (§)

From the  (1)Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, La Jolla, California 92093, the Veteran's Administration Medical Center, Medical Research Service, San Diego, California 92161, the First Department of Medicine, Toyama Medical and Pharmaceutical University, Toyama 930-01, Japan, and the (2)Department of Signal Transduction, Parke-Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 48105

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Insulin and epidermal growth factor receptors transmit signals for cell proliferation and gene regulation through formation of active GTP-bound p21 mediated by the guanine nucleotide exchange factor Sos. Sos is constitutively bound to the adaptor protein Grb2 and growth factor stimulation induces association of the Grb2/Sos complex with Shc and movement of Sos to the plasma membrane location of p21. Insulin or epidermal growth factor stimulation induces a rapid increase in p21 levels, but after several minutes levels decline toward basal despite ongoing hormone stimulation. Here we show that deactivation of p21correlates closely with phosphorylation of Sos and dissociation of Sos from Grb2, and that inhibition of mitogen-activated protein (MAP) kinase kinase (also known as extracellular signal-related kinase (ERK) kinase, or MEK) blocks both events, resulting in prolonged p21 activation. These data suggest that a negative feedback loop exists whereby activation of the Raf/MEK/MAP kinase cascade by p21 causes Sos phosphorylation and, therefore, Sos/Grb2 dissociation, limiting the duration of p21 activation by growth factors. A serine/threonine kinase downstream of MEK (probably MAP kinase) mediates this desensitization feedback pathway.


INTRODUCTION

The tyrosine kinase receptors for insulin, EGF, (^1)and other growth factors mediate cell proliferation and gene regulation, and it has been demonstrated that activation of p21 is essential for these effects(1, 2) . p21 is one of a family of closely related membrane-bound guanine nucleotide-binding proteins, which bind GTP and catalyze its hydrolysis to GDP. The GTP-bound protein is active, while the GDP-bound form is not. The GTPase-activating protein GAP promotes inactivation of p21 by stimulating the hydrolysis of GTP (3) , whereas the guanine nucleotide exchange factor (GEF) Sos (homologue of the Drosophila Son-of-sevenless protein) mediates activation by inducing the release of GDP(4, 5, 6, 7, 8) . In the case of insulin and EGF, activation of p21 has been shown to be mediated by Sos rather than by GAP(8, 9) .

In the basal state, Sos is a cytoplasmic protein constitutively bound to the adaptor protein Grb2. This interaction is mediated by the two Src homology 3 (SH3) domains of Grb2, which bind to proline-rich regions in the C terminus of Sos(6, 10, 11, 12) . Insulin or EGF stimulation results in the translocation of Sos to the plasma membrane, where activation of p21 occurs(5). Growth factor stimulation also results in the tyrosine phosphorylation of the intermediary signaling molecule Shc on a tyrosine residue in a consensus binding motif for the Grb2 SH2 domain, resulting in the binding of the Grb2/Sos complex to Shc(6, 11) . In the case of the EGF receptor the mechanism for targeting Sos to the plasma membrane is binding of the SH2 domain or phosphotyrosine binding domain of Shc to phosphotyrosine residues of the EGF receptor(5, 13, 14, 15) ; direct binding of the Grb2 SH2 domain to the EGF receptor most likely plays a lesser role(16) . There is evidence that Shc plays a key role upstream of p21 in the mitogenic response to both insulin and EGF, suggesting that in fact the trimeric Shc/Grb2/Sos complex is important for activation of p21(16, 17, 18, 19) .

The pattern of p21 activation after growth factor stimulation is one of a rapid increase in GTP binding, peaking in the first several minutes and then falling rather rapidly toward basal levels despite ongoing ligand stimulation(10, 20, 21, 22, 23, 24) . The mechanism of this down-regulation is unknown. However, it has recently been demonstrated that Sos undergoes serine/threonine phosphorylation following growth factor stimulation(24, 25, 26) , and dissociation of the Grb2/Sos complex appears to correlate temporally with Sos phosphorylation(24, 25) . The purpose of this study was to elucidate the serine kinase pathway leading to Sos phosphorylation and to determine whether Grb2/Sos dissociation is causally related. In addition, we sought to learn whether this dissociation is a negative feedback mechanism resulting in the desensitization of p21to prolonged activation by growth factor stimulation.


EXPERIMENTAL PROCEDURES

Materials

Rat1 cells expressing wild type human insulin receptors (HIRc) were maintained as described previously(27) . Insulin was kindly provided by Lilly. Polyclonal antibodies used for immunoprecipitations were from sources as follows: anti-Sos1, Upstate Biotechnology (Lake Placid, NY); anti-Grb2, Santa Cruz Biotechnology (Santa Cruz, CA); anti-Shc, Transduction Laboratories (Lexington, KY). Monoclonal antibodies anti-Sos1, anti-Grb2 and anti-phosphotyrosine (PY20) used for immunoblotting were all from Transduction Laboratories. The rat anti-p21 antibody was from Santa Cruz Biotechnology, and the rabbit anti-rat antiserum was from Cappell (Durham, NC). Carrier-free [P]orthophosphate (40 mCi/ml) was from DuPont NEN. Polyethyleneimine cellulose TLC plates were from J.T.Baker (Phillipsburg, NJ). Electrophoresis reagents were from Bio-Rad. Enhanced chemiluminescence reagents were from Amersham Corp. All other reagents were purchased from Sigma.

Immunprecipitation and Western Blotting Studies

HIRcB cells were serum-starved for 16 h, and then treated for 60 min with 20 µM PD098059 in 1% Me(2)SO, or 1% Me(2)SO alone. Cells were then stimulated with 17 nM insulin or 160 nM EGF for the indicated times. The cells were washed twice in ice-cold phosphate-buffered saline and collected in lysis buffer consisting of 25 mM HEPES, pH 7.4, 120 mM NaCl, 5 mM KCl, 1 mM MgSO(4), 1 mM CaCl(2), 1% Triton X-100, 1% glycerol, 1 mM phenylmethylsulfonyl fluoride, 800 KIU/ml aprotinin, 8 mM EDTA, 0.5 mg/ml bacitracin, 2 mM dichloroacetic acid, 15 mM benzamidine, 160 mM NaF, 2 mM Na(3)VO(4), 10 mM Na(4)P(2)O(7)bullet10 H(2)O. Lysates were clarified by centrifugation, and the supernatants were divided for immunoprecipitation with polyclonal antibodies to Sos, Grb2, or Shc. Immunoprecipitations were performed for 4 h at 4 °C with the addition of protein A-agarose for the final hour, and the pellets were washed three times and boiled in SDS-PAGE sample buffer. Samples were resolved on 5-15% SDS-PAGE gels and electroblotted onto nitrocellulose. After blocking in 50 mM Tris-HCl, pH 7.5, NaCl 150 mM, 0.1% Tween 20, and 2.5% bovine serum albumin, membranes were incubated with the indicated primary antibody, washed, incubated with 1/1000 dilution of Amersham sheep anti-mouse Fc horseradish peroxidase-linked antibody, washed, and developed by ECL (Amersham).

Measurement of GTP- and GDP-bound p21

Confluent 60-mm dishes of HIRcB cells were serum-starved for 24 h and labeled with 0.5 mCi of [P]orthophosphate/dish for 4 h. During the final hour of labeling, 20 µM PD098059 with 1% Me(2)SO, or 1% Me(2)SO alone, was added. After labeling, cells were stimulated with 17 nM insulin for the indicated times, and quantitation of p21-bound GTP and GDP was performed essentially as described(20) . Medium was aspirated, and cells were washed twice in ice-cold Tris-buffered saline and lysed in 1 ml of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM MgCl(2), 0.5% Nonidet P-40, 10 µg/ml aprotinin, 1% phenylmethylsulfonyl fluoride, and 1 mM Na(3)VO(4). The lysates were cleared by centrifugation, excess free nucleotides were removed by incubation with activated charcoal, and samples were frozen in a dry ice/methanol bath. After thawing at 37 °C for 3 min, anti-Ras monoclonal rat antibody Y13-259 and protein A-agarose precoupled to rabbit anti-rat IgG were added for 1 h at 4 °C. Immune complexes were washed twice with lysis buffer and twice with lysis buffer lacking Nonidet P-40, and nucleotides were eluted in 20 mM Tris-HCl, pH 7.5, 20 mM EDTA, 2% SDS, 0.5 mM GTP, and 0.5 mM GDP by heating at 65 °C for 5 min. Thin layer chromatography was performed on polyethyleneimine cellulose in 0.75 M KH(2)PO(4), pH 3.4. Results were quantitated directly using a PhosphorImager.


RESULTS AND DISCUSSION

Growth factor-induced serine/threonine phosphorylation of Sos is mediated by kinases downstream of Raf1 in the Raf1/MEK/MAP kinase cascade activated by p21(28) . To examine the role of Sos phosphorylation in insulin signaling, an inhibitor of MEK activity, PD098059, was used. This compound is relatively specific for MEK with no inhibitory activity against a number of other serine/threonine and tyrosine kinases(29) . Insulin stimulation of HIRcB cells, a Rat1 fibroblast line expressing the human insulin receptor, resulted in a significant retardation of mobility of Sos on SDS-PAGE, reflecting Sos phosphorylation (Fig. 1A, lanes 1-6). This occurred first between 1 and 5 min of stimulation and was maximal by 10 min, decreasing somewhat by 120 min. The breadth of the Sos signal at 5 and 120 min may reflect a mix of more and less highly phosphorylated Sos phosphoprotein species, as Sos has at least two phosphorylation sites(30) .


Figure 1: Effects of insulin with or without MEK inhibition on Sos phosphorylation and binding between Sos, Grb2, and Shc. Serum-starved cells were treated with either the MEK inhibitor PD098059 or vehicle alone for 1 h, then stimulated with insulin for the indicated times. Cells lysates were divided for analysis by immunoprecipitation and immunoblotting with the indicated antibodies. A, Sos phosphorylation and mobility shift; B, Sos coprecipitation with Grb2; C, Sos coprecipitation with Shc; D, Grb2 coprecipitation with Shc; E, tyrosine phosphorylation of Shc. Results are representative of three separate experiments. IP, immunoprecipitation; IB, immunoblotting.



Grb2 has two Src homology 3 (SH3) domains, which bind to proline-rich regions in the C terminus of Sos(11, 12) . Coimmunoprecipitation studies of Grb2 and Sos showed that Grb2/Sos complexes were present in the basal state, but after insulin treatment these complexes rapidly dissociated such that they were undetectable (Fig. 1B, lanes 1-6). Some reassociation was seen at the later time points as Sos became dephosphorylated. Pretreatment of the cells with the MEK inhibitor prevented Sos phosphorylation (Fig. 1A, lanes 7-12) and Grb2/Sos dissociation (Fig. 1B, lanes 7-12). This strongly suggests that Sos phosphorylation causes dissociation of Sos from Grb2. This is further supported by the observation that the Sos which was complexed with Grb2 at 5 and 40 min showed only minimal mobility shift compared to total cellular Sos, suggesting that the Sos which remained bound to Grb2 represented a subpopulation of Sos that was less heavily phosphorylated. MAP kinase has been shown to phosphorylate Sos in vitro(30) , and there are several MAP kinase consensus phosphorylation sequences in the C terminus of Sos(31, 32) , suggesting that phosphorylation of Sos by MAP kinase may disrupt binding of Sos to the SH3 domains of Grb2.

Insulin stimulation leads to binding of the Grb2 SH2 domain to tyrosine-phosphorylated Shc, which plays a key role in insulin-stimulated mitogenesis, presumably by targeting Sos to the plasma membrane where it activates p21(19, 33, 34). Thus, the importance of Grb2/Sos dissociation may be that it decreases linkage of Sos to Shc. Consistent with this notion, Shc/Sos coprecipitation studies showed only a transient association, seen at 1 and 5 min and gone by 10 min (Fig. 1C, lanes 1-6), while in cells treated with PD098059, the Sos/Shc interaction persisted for 120 min (Fig. 1C, lanes 7-12). Shc/Grb2 coimmunoprecipitation analysis revealed minimal or no basal coprecipitation; insulin treatment induced significant Shc/Grb2 association by 1 min, which was maximal by 5 min and unchanged thereafter, and was unaffected by the MEK inhibitor (Fig. 1D). As expected, Shc/Grb2 association correlated closely with the time course of Shc tyrosine phosphorylation (Fig. 1E), which was also unaffected by the inhibitor. Thus, initial formation of the Shc/Grb2/Sos complex is caused by binding of preformed Grb2/Sos complexes to tyrosine-phosphorylated Shc. However, disassembly of the Shc/Grb2/Sos trimer is caused by rapid phosphorylation of Sos and dissociation of Sos from Grb2, leaving the Shc/Grb2 complex intact, while Sos becomes free (and presumably unable to activate p21). As Shc remains bound to Grb2, it is unavailable to bind to any residual free Grb2/Sos complexes, which might otherwise contribute to p21 activation. MEK inhibition blocks Sos phosphorylation and Grb2/Sos dissociation, resulting in Shc/Grb2/Sos complexes persisting throughout insulin treatment.

p21 activation, as reflected by the percentage of the protein in the GTP-bound state, is transient, despite ongoing growth factor stimulation(10, 20, 21, 22, 23, 24) . p21 activation by insulin in HIRcB cells was transient, with peak p21-GTP levels by 7 min and a subsequent rapid decline (Fig. 2). This correlates closely with the time course of Shc/Grb2/SOS association (Fig. 1C), which peaked at 5 min and fell by 10 min. In contrast, MEK inhibition resulted in prolonged stimulation of p21-GTP, with peak levels not seen until 15 min, and only a gradual decline thereafter. Taken together, the data strongly suggest that dissociation of SOS from Grb2 plays a key role in limiting the duration of activation of p21 in response to ongoing insulin stimulation. This would be analogous to a negative feedback loop described in Saccharomyces cerevisiae, in which glucose induced elevated levels of cAMP via a Ras/adenylyl cyclase pathway activated by the GEF Cdc25. The resultant rapid activation of cAMP-dependent protein kinase then caused phosphorylation of Cdc25 and caused it to dissociate from Ras, resulting in Ras deactivation(35) .


Figure 2: Time course of p21 activation by insulin with or without MEK inhibition. Quiescent HIRcB cells labeled with [P]orthophosphate were treated with 20 µM PD098059 (circle) or vehicle only () for 1 h and then stimulated with insulin for the indicated times. p21 was isolated by immunoprecipitation, and the p21-bound labeled guanine nucleotides were eluted and analyzed by TLC. Results were quantitated directly by PhosphorImager and are expressed as GTP/(GTP + GDP) times 100%. Data are the mean values of two separate experiments.



Rat1 fibroblasts express 10^5 EGF receptors/cell, and a similar analysis of the association patterns of Shc, Grb2, and Sos upon EGF stimulation was performed. EGF also caused Sos phosphorylation (Fig. 3A), and this was correlated with dissociation from Grb2 and from Shc (Fig. 3, B and C). The MEK inhibitor PD098059 prevented Sos phosphorylation, as well as dissociation of Sos from Grb2 and Shc ((Fig. 3, A-C). Interestingly, the association of Grb2 with Shc, illustrated in Fig. 3D, occurred rapidly but was not as sustained as it was with insulin stimulation (Fig. 1D). This may reflect down-regulation of the low number of endogenous EGFRs, and could explain why at 60 and 120 min there was only a minimal Sos mobility shift (Fig. 3A, lanes 5 and 6), and significant Grb2/Sos reassociation (Fig. 3B, lanes 5 and 6). Furthermore, it explains why, in the presence of PD098059, Sos coprecipitation with Shc declines by 30 min (i.e. although Sos and Grb2 remain in a complex, much of Grb2 has dissociated from Shc). Interestingly, while some Grb2/Sos reassociation was seen at 40 and 120 min, there was no concomitant coprecipitation of Sos with Shc (Fig. 3C, lanes 5 and 6), suggesting that only Grb2 already dissociated from Shc reassociated with Sos. Thus, the phenomenon of Sos phosphorylation, with Grb2/Sos complex dissociation reducing the duration of existence of the active Shc/Grb2/Sos complex, is also observed with signaling through the EGF receptor.


Figure 3: Effects of EGF with or without MEK inhibition on Sos phosphorylation and binding between Sos, Grb2 and Shc. Serum-starved cells were treated with either the MEK inhibitor PD098059 or vehicle alone for 1 h, then stimulated with EGF for the indicated times. Cells lysates were divided for analysis by immunoprecipitation and immunoblotting with the indicated antibodies. A, Sos phosphorylation and mobility shift; B, Sos coprecipitation with Grb2; C, Sos coprecipitation with Shc; D, Grb2 coprecipitation with Shc. Results are representative of two separate experiments. IP, immunoprecipitation; IB, immunoblotting.



Prolonged p21 activation, either by oncogenic forms of p21(36) or by activation of endogenous p21 by the introduction of upstream activators such as membrane-targeted Sos (34) , is a transforming event that plays a significant role in many malignancies(37) . Thus, tight control of p21 activation is important in growth regulation. Growth factors typically cause a transient rise in p21-GTP formation and the subsequent fall back to base-line values serves to attenuate the hormonal signal, and may make cells refractory to subsequent growth factor stimulation. The current studies indicate that the mechanism underlying this attenuation process involves hyperphosphorylation of Sos on serine/threonine residues with subsequent dissociation of Grb2/Sos complexes; p21 activates the MAP kinase pathway, and this feedback signal is generated from MEK or a serine/threonine kinase downstream of MEK.


FOOTNOTES

*
This work was supported in part by NIDDK National Institutes of Health Grant DK33651, by the Veterans Administration Medical Research Service, and by a fellowship grant from the Medical Research Council of Canada (to W. J. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Medicine (0673), University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0673. Tel.: 619-534-6651; Fax: 619-534-6653.

(^1)
The abbreviations used are: EGF, epidermal growth factor; GEF, guanine nucleotide exchange factor; SH, Src homology; TLC, thin layer chromatography; PAGE, polyacrylamide gel electrophoresis; GAP, GTPase-activating protein; MAP, mitogen-activated protein; ERK, extracellular signal-related kinase; MEK, MAP kinase/ERK kinase.


ACKNOWLEDGEMENTS

We thank L. Collins for assistance with the p21-GTP assay.


REFERENCES

  1. Burgering, B. M. T., Medema, R. H., Maassen, J. A., van de Wetering, M. L., van der Eb, A. J., McCormick, F., and Bos, J. L. (1991) EMBO J. 5, 1103-1109
  2. Jhun, B. H., Meinkoth, J. L., Leitner, J. W., Draznin, B., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 5699-5704 [Abstract/Free Full Text]
  3. Trahey, M., and McCormick, F. (1987) Science 238, 542-545 [Medline] [Order article via Infotrieve]
  4. Simon, M. A., Bowtell, D. D. L., Dodson, G. S., Laverty, T. R., and Rubin, G. M. (1991) Cell 67, 701-716 [Medline] [Order article via Infotrieve]
  5. Buday, L., and Downward, J. (1993) Cell 73, 611-620 [Medline] [Order article via Infotrieve]
  6. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. (1993) Nature 363, 45-51 [CrossRef][Medline] [Order article via Infotrieve]
  7. Baltensperger, K., Kozma, L. M., Cherniak, A. D., Klarlund, J. K., Chawla, A., Banerjee, U., and Czech, M. P. (1993) Science 260, 1950-1952 [Medline] [Order article via Infotrieve]
  8. Medema, R. H., de Vries-Smits, A. M. M., van der Zon, G. C. M., Maassen, J. A., and Bos, J. L. (1993) Mol. Cell. Biol. 13, 155-162 [Abstract]
  9. Draznin, B., Chang, L., Leitner, J. W., Takata, Y., and Olefsky, J. M. (1993) J. Biol. Chem. 268, 19998-20001 [Abstract/Free Full Text]
  10. Chardin, P., Camonis, J. H., Gale, N. W., Van Aelst, L., Schlessinger, J., Wigler, M. H., and Bar-Sagi, D. (1993) Science 260, 1338-1343 [Medline] [Order article via Infotrieve]
  11. Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T., and Bowtell, D. (1993) Nature 363, 83-85 [CrossRef][Medline] [Order article via Infotrieve]
  12. Li, N., Batzer, A., Daly, R., Yajnik, V., Skolnik, E., Chardin, P., Bar-Sagi, D., Margolis, B., and Schlessinger, J. (1993) Nature 363, 85-88 [CrossRef][Medline] [Order article via Infotrieve]
  13. Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., Pawson, T., and Pelicci, P. G. (1992) Cell 70, 93-104 [Medline] [Order article via Infotrieve]
  14. Kavanaugh, W. M., and Williams, L. T. (1994) Science 266, 1862-1865 [Medline] [Order article via Infotrieve]
  15. Blaikie, P., Immanuel, D., Wu, J., Li, N., Yajnik, V., and Margolis, B. (1994) J. Biol. Chem. 269, 32031-32034 [Abstract/Free Full Text]
  16. Sasaoka, T., Langlois, W. J., Leitner, J. W., Draznin, B., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 32621-32625 [Abstract/Free Full Text]
  17. Sasaoka, T., Draznin, B., Leitner, J. W., Langlois, W. J., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 10734-10738 [Abstract/Free Full Text]
  18. Sasaoka, T., Rose, D. W., Jhun, B. H., Saltiel, A. R., Draznin, B., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 13689-13694 [Abstract/Free Full Text]
  19. Pronk, G. J., de Vries-Smits, A. M. M., Buday, L., Downward, J., Maassen, J. A., Medema, R. H., and Bos, J. L. (1994) Mol. Cell. Biol. 14, 1575-1581 [Abstract]
  20. Gibbs, J. B., Marshall, M. S., Scolnick, E. M., Dixon, R. A. F., and Vogel, U. S. (1990) J. Biol. Chem. 265, 20437-20442 [Abstract/Free Full Text]
  21. Nakafuku, M., Satoh, T., and Kaziro, Y. (1992) J. Biol. Chem. 267, 19448-19454 [Abstract/Free Full Text]
  22. Buday, L., and Downward, J. (1993) Mol. Cell. Biol. 13, 1903-1910 [Abstract]
  23. Hashimoto, Y., Matuoka, K., Takenawa, T., Muroya, K., Hattori, S., and Nakamura, S. (1994) Oncogene 9, 869-875 [Medline] [Order article via Infotrieve]
  24. Cherniack, A. D., Klarlund, J. K., Conway, B. R., and Czech, M. P. (1995) J. Biol. Chem. 270, 1485-1488 [Abstract/Free Full Text]
  25. Waters, S. B., Yamauchi, K., and Pessin, J. E. (1995) Mol. Cell. Biol. 15, 2791-2799 [Abstract]
  26. de Vries-Smits, A. M. M., Pronk, G. J., Medema, J. P., Burgering, B. M. T., and Bos, J. L. (1995) Oncogene 10, 919-925 [Medline] [Order article via Infotrieve]
  27. McClain, D. A., Maegawa, H., Lee, J., Dull, T. J., Ullrich, A., and Olefsky, J. M. (1987) J. Biol. Chem. 262, 14663-14671 [Abstract/Free Full Text]
  28. Burgering, B. M. T., Pronk, G. J., van Weeren, P. C., Chardin, P., and Bos, J. L. (1993) EMBO J. 12, 4211-4220 [Abstract]
  29. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. J. (1995) Proc. Natl. Acad. Sci. U. S. A. , in press
  30. Cherniack, A. D., Klarlund, J. K., and Czech, M. P. (1994) J. Biol. Chem. 269, 4717-4720 [Abstract/Free Full Text]
  31. Gonzalez, F. A., Raden, D. L., and Davis, R. J. (1991) J. Biol. Chem. 266, 22159-22163 [Abstract/Free Full Text]
  32. Clark-Lewis, I., Sanghera, J. S., and Pelech, S. L. (1991) J. Biol. Chem. 266, 15180-15184 [Abstract/Free Full Text]
  33. Sasaoka, T., Draznin, B., Leitner, J. W., Langlois, W. J., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 10734-10738 [Abstract/Free Full Text]
  34. Aronhein, A., Engelberg, D., Li, N., al-Alawi, N., Schlessinger, J., and Karin, M. (1994) Cell 78, 949-961 [Medline] [Order article via Infotrieve]
  35. Gross, E., Goldberg, D., and Levitzki, A. (1992) Nature 360, 762-765 [CrossRef][Medline] [Order article via Infotrieve]
  36. Stacey, D. M., and Kung, H. F. (1984) Nature 310, 508-511 [Medline] [Order article via Infotrieve]
  37. Bos, J. L. (1989) Cancer Res. 49, 4682-4689 [Abstract]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.